Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Onur Eroglu"'
Autor:
Hacer Kaya Cakir, Onur Eroglu
Publikováno v:
Asian Pacific Journal of Reproduction, Vol 12, Iss 5, Pp 201-210 (2023)
Objective: To give a brief overview of the field of epigenetics and the potential predictive power that small non-coding RNA (sncRNA) may hold in relation to improving the treatment and diagnosis of male infertility. Methods: PRISMA-ScR was used as t
Externí odkaz:
https://doaj.org/article/1697943bec7b48348be8acfb45db7962
Autor:
Hacer Kaya Cakır, Onur Eroglu
Publikováno v:
Iranian Journal of Basic Medical Sciences, Vol 24, Iss 11, Pp 1515-1522 (2021)
Objective(s): Mouse breast cancer cell line 4T1 can accurately mimic the response to immune receptors and targeting therapeutic agents. Combined therapy has emerged as an important strategy with reduced side effects and maximum therapeutic effect. Mo
Externí odkaz:
https://doaj.org/article/2ba6994484584ce4aa8d5aa7cab47d59
Autor:
Kubra Erdogan, Onur Eroglu
Publikováno v:
Proceedings, Vol 40, Iss 1, p 18 (2019)
Glioblastoma multiforme (GBM) is a type of cancer which has the highest mortality rate among brain cancers (1–2). Momordica charantia, known as bitter melon, is a plant its pharmacological activities and nutritional properties. Due to contains bioa
Externí odkaz:
https://doaj.org/article/de63e39674f148cf828d5536683778be
Autor:
Esin Guvenir Celik, Onur Eroglu
Publikováno v:
Molecular Biology Reports. 50:319-329
Due to deficiencies in the expression of hormone receptors, such as PR, ER and HER2, it is challenging to treat triple-negative breast cancer, which does not respond to single targeted therapy. Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor. MK-
Autor:
Esin Guvenir Celik, Onur EROGLU
Background: Due to deficiencies in the expression of hormone receptors, such as PR, ER and HER2, it is challenging to treat triple-negative breast cancer (TNBC), which does not respond to single targeted therapy. Ruxolitinib is a Janus kinase (JAK)1/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77719625039cd16df5c73996c67dd833
https://doi.org/10.21203/rs.3.rs-1954138/v1
https://doi.org/10.21203/rs.3.rs-1954138/v1
Autor:
Yakup Dülgeroğlu, Onur Eroglu
Publikováno v:
MicroRNA. 9:303-309
Introduction: Prostate Cancer (PCa) is the second most common cancer in males and the fifth in cancer-associated mortality. Although the Prostate-Specific Antigen (PSA) test is widely used in PCa screenings, it has significant limitations in the diff
Autor:
Esin Guvenir Celik, Hilmi Uysal, Hacer Kaya, Sibel Berker Karauzum, Onur Eroglu, Ceren Hangul
Publikováno v:
Turkish Journal of Biochemistry. 46:435-444
Objectives There is a clinical variability and heterogeneity among Facioscapulohumeral Muscular Dystrophy (FSHD) patients. Escalation after menopause in women, early onset in men suggests that estrogen might be a protective factor on the course of FS
Publikováno v:
Journal of Biosciences and Medicines. :74-85
Purpose: Investigating the triple effect of doxorubicin, 5-fluorouracil, propranolol on MCF-7 (ER+, WTp53) breast cancer cell line with MTT test and survival analysis. Materials/Methods: In order to determine effective dosages of a combination of dox
Publikováno v:
Advances in Breast Cancer Research. :45-59
BACKGROUND: Promoter hypermethylation and global hypomethylation in the human genome are hallmarks of most cancers. OBJECTIVE: The aim of this study is to assess the methylation profile patterns of TWIST gene and to investigate the relationship of me
Autor:
Merve Celen, Onur Eroglu
Publikováno v:
Journal of Cancer Therapy. 10:229-244
The aim of this study is to investigate the anti-proliferative effects of Zebularine on caspase-3 and 9 genes by methylation and protein expression on SKBR3 cells. The SKBR3 cells were treated with Zebularine at different concentrations (0 - 140 μM)